REGN vs SER · P/E 14, rev $14.34B vs rev $56.0K
Regeneron Pharmaceuticals Inc (REGN) versus Serina Therapeutics Inc (SER) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Serina Therapeutics Inc (SER) is a biotechnology company listed on AMEX.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported SER revenue for 2024-12-31 was $56.0K. Net income was -$11.2M. Revenue was down 98.2% from 2023-12-31 to 2024-12-31. SER currently screens at market cap $29.7M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SER currently screens at market cap $29.7M.
Not investment advice. Open the REGN and SER stock pages for the full models.
Not investment advice.